Treatment of recurrent urinary tract infection with norfloxacin versus trimethoprim-sulfamethoxazole. 1990

E J Seidmon, and E B Krisch, and A L Truant, and B G Amy, and S J Childs, and A T Hurst, and R E McCabe
Department of Urology, Temple University School of Medicine, Philadelphia, Pennsylvania.

Norfloxacin, a broad-spectrum antimicrobial analog of nalidixic acid, was evaluated by comparing it to trimethoprim-sulfamethoxazole in 93 office patients with recurrent urinary tract infections. In this prospective randomized study, norfloxacin and trimethoprim-sulfamethoxazole were given on the same dosage schedule with the former drug given as a 400-mg tablet twice daily and the latter drug given as a double strength tablet twice daily. Overall, 50 patients received norfloxacin and 43 patients received trimethoprim-sulfamethoxazole with a cure rate of 96 percent and 79 percent, respectively. Whether a patient had one infection or multiple previous infections, norfloxacin appeared to be superior to trimethoprim-sulfamethoxazole. Only minor side effects were noted in either group, and no patient withdrew from this study as a direct result of these side effects. Minor complaints of nausea, dizziness, and headache were found in the norfloxacin group (24%) and in the trimethoprim-sulfamethoxazole group (16%). Both agents are effective in treating urinary tract infections but norfloxacin is superior to trimethoprim-sulfamethoxazole in patients with either recurrent complicated infections or one previous uncomplicated urinary tract infection.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009643 Norfloxacin A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE. AM-0715,AM-715,MK-0366,MK-366,MK0366,MK366,Noroxin,AM 0715,AM 715,AM0715,MK 0366,MK 366
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004927 Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI. E coli Infections,E. coli Infection,Infections, E coli,Infections, Escherichia coli,E coli Infection,E. coli Infections,Escherichia coli Infection,Infection, E coli,Infection, E. coli,Infection, Escherichia coli
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

E J Seidmon, and E B Krisch, and A L Truant, and B G Amy, and S J Childs, and A T Hurst, and R E McCabe
January 1990, European urology,
E J Seidmon, and E B Krisch, and A L Truant, and B G Amy, and S J Childs, and A T Hurst, and R E McCabe
February 1987, The Journal of infectious diseases,
E J Seidmon, and E B Krisch, and A L Truant, and B G Amy, and S J Childs, and A T Hurst, and R E McCabe
November 1973, The Journal of infectious diseases,
E J Seidmon, and E B Krisch, and A L Truant, and B G Amy, and S J Childs, and A T Hurst, and R E McCabe
November 1973, The Journal of infectious diseases,
E J Seidmon, and E B Krisch, and A L Truant, and B G Amy, and S J Childs, and A T Hurst, and R E McCabe
May 1974, The Journal of urology,
E J Seidmon, and E B Krisch, and A L Truant, and B G Amy, and S J Childs, and A T Hurst, and R E McCabe
April 1974, Canadian Medical Association journal,
E J Seidmon, and E B Krisch, and A L Truant, and B G Amy, and S J Childs, and A T Hurst, and R E McCabe
January 1992, Clinical therapeutics,
E J Seidmon, and E B Krisch, and A L Truant, and B G Amy, and S J Childs, and A T Hurst, and R E McCabe
November 1970, Nordisk medicin,
E J Seidmon, and E B Krisch, and A L Truant, and B G Amy, and S J Childs, and A T Hurst, and R E McCabe
March 1985, Antimicrobial agents and chemotherapy,
E J Seidmon, and E B Krisch, and A L Truant, and B G Amy, and S J Childs, and A T Hurst, and R E McCabe
June 1997, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!